ADVFN - ニュース

S&P 500

5,460.48

-0.41%

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

該当コードがありません。

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/07/01	14 : 55	GlobeNewswire Inc.	Share repurchase programme	TG:JYS1	Jyske Bank AS
2024/07/01	14 : 55	GlobeNewswire Inc.	Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week	NASDAQ:MESO	Mesoblast Limited
2024/07/01	14 : 55	GlobeNewswire Inc.	Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week	MSB.AX
2024/07/01	14 : 53	Alliance News	US bases in Europe on high alert amid possible terror threat
2024/07/01	14 : 50	Alliance News	Airbus says will buy "major activities" of subcontractor Spirit
2024/07/01	14 : 49	Alliance News	LONDON MARKET EARLY CALL: FTSE 100 called up on week of UK election
2024/07/01	14 : 49	Business Wire	MOGAS signe un contrat pour soutenir la nouvelle technologie TC2C™
2024/07/01	14 : 49	Business Wire	モガス、TC2C™新技術のサポート契約を獲得
2024/07/01	14 : 49	Business Wire	MOGAS erhält Auftrag zur Unterstützung der neuen TC2C™-Technologie
2024/07/01	14 : 45	GlobeNewswire Inc.	Wendel joins Providence to support Globeducate, a leading international K-12 education group, through its next phase of growth	TG:WIS	Wendel SA
2024/07/01	14 : 45	GlobeNewswire Inc.	Wendel et Providence accompagneront conjointement Globeducate, un groupe d’écoles internationales de la maternelle au secondaire, dans sa prochaine phase de croissance	EU:MF	Wendel SA
2024/07/01	14 : 45	GlobeNewswire Inc.	Wendel joins Providence to support Globeducate, a leading international K-12 education group, through its next phase of growth	EU:MF	Wendel SA
2024/07/01	14 : 45	GlobeNewswire Inc.	Wendel et Providence accompagneront conjointement Globeducate, un groupe d’écoles internationales de la maternelle au secondaire, dans sa prochaine phase de croissance	TG:WIS	Wendel SA
2024/07/01	14 : 45	GlobeNewswire Inc.	Sword Group: Acquisitions in the UK	TG:9RS	Sword Group
2024/07/01	14 : 45	GlobeNewswire Inc.	Sword Group: Acquisitions in the UK	EU:SWP	Sword Group
2024/07/01	14 : 45	GlobeNewswire Inc.	Sword Group : Acquisitions en Grande-Bretagne	EU:SWP	Sword Group
2024/07/01	14 : 45	GlobeNewswire Inc.	Sword Group : Acquisitions en Grande-Bretagne	LSE:0MN5	Sword Group Se
2024/07/01	14 : 45	GlobeNewswire Inc.	Sword Group : Acquisitions en Grande-Bretagne	TG:9RS	Sword Group
2024/07/01	14 : 45	GlobeNewswire Inc.	Sword Group: Acquisitions in the UK	LSE:0MN5	Sword Group Se
2024/07/01	14 : 38	Alliance News	Irish slowdown in manufacturing accelerates in June; outlook positive
2024/07/01	14 : 33	PR Newswire (US)	Global Times: CPC members reach 99.185 million
2024/07/01	14 : 31	GlobeNewswire Inc.	Kalmar’s financial information in 2024
2024/07/01	14 : 30	Alliance News	GET READY: Induction Healthcare Group, Porvair at 0700 BST	LSE:INHC	Induction Healthcare Group Plc
2024/07/01	14 : 30	Alliance News	GET READY: Induction Healthcare Group, Porvair at 0700 BST	LSE:PRV	Porvair Plc
2024/07/01	14 : 30	Alliance News	Alliance News UK - start of day
2024/07/01	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’	EU:OSE	OSE Immunotherapeutics
2024/07/01	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’	LSE:0RAD	Ose Immunotherapeutics Sa
2024/07/01	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’	EU:OSE	OSE Immunotherapeutics
2024/07/01	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’	LSE:0RAD	Ose Immunotherapeutics Sa
2024/07/01	14 : 30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’	TG:6OP	OSE Immunotherapeutics